M&A Deal Summary

Sorrento Therapeutics Acquires SCILEX Pharmaceuticals

On August 8, 2016, Sorrento Therapeutics acquired life science company SCILEX Pharmaceuticals

Acquisition Highlights
  • This is Sorrento Therapeutics’ 3rd transaction in the Life Science sector.
  • This is Sorrento Therapeutics’ 3rd transaction in the United States.
  • This is Sorrento Therapeutics’ 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2016-08-08
Target SCILEX Pharmaceuticals
Sector Life Science
Buyer(s) Sorrento Therapeutics
Deal Type Add-on Acquisition

Target

SCILEX Pharmaceuticals

Malvern, Pennsylvania, United States
SCILEX Pharmaceuticals, Inc. develops and brings branded pharmaceutical products to market using technologies that are designed to maximize quality of life for all. SCILEX is working to deliver the next generation of products that are responsible by design. The Company's lead product candidate under development, ZTlido (lidocaine patch 1.8%), is a branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sorrento Therapeutics

San Diego, California, United States

Category Company
Founded 2006
Sector Life Science
Employees949
Revenue 63M USD (2022)
DESCRIPTION

Sorrento Therapeutics is an oncology company that is involved in the development of small molecules, mono- and bi-specific antibodies and antibody drug conjugates for treatment of cancer and associated pain. Sorrento Therapeutics was founded in 2006 and is based in San Diego, California.


DEAL STATS #
Overall 3 of 9
Sector (Life Science) 3 of 9
Type (Add-on Acquisition) 3 of 7
State (Pennsylvania) 1 of 1
Country (United States) 3 of 8
Year (2016) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-15 IgDraSol

Fountain Valley, California, United States

IgDraSol, Inc. is a pharamaceutal company focused on the development of oncologic agents for the treatment of metastatic breast cancer (“MBC”), non-small cell lung cancer (“NSCLC”), and other cancers.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-15 Semnur Pharmaceuticals

Los Altos, California, United States

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients. Semnur's primary focus lies in the development of non-opioid products for meeting the needs of underserved patients with back pain. Semnur believes that the therapeutic advantages of their product and technology will improve products' efficacy and safety making a substantial improvement in the treatment of back pain.

Buy -